Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: A longstanding controversy deciphered

British Journal of Haematology

Volumn 171, Issue 2, 2015, Pages 227-238

  Zeijlemaker, Wendelien ^a   Kelder, Angèle ^a   Wouters, Rolf ^a   Valk, Peter J M ^b   Witte, Birgit I ^a   Cloos, Jacqueline ^a   Ossenkoppele, Gert J ^a   Schuurhuis, Gerrit J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukaemia; CD34; Flow cytometry; Minimal residual disease; Prognosis

Indexed keywords

CD34 ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CD34 SELECTION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84942988506     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13572     Document Type: Article

References (52)

1. Arslan, O., Akan, H., Beksac, M., Ozcan, M., Koc, H., Ilhan, O., Konuk, N. & Uysal, A. (1996) Lack of prognostic value of CD34 in adult AML. Leukemia & Lymphoma, 23, 185-186.
2. Bachas, C., Schuurhuis, G.J., Assaraf, Y.G., Kwidama, Z.J., Kelder, A., Wouters, F., Snel, A.N., Kaspers, G.J.L. & Cloos, J. (2012) The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia, 26, 1313-1320.
3. Benderra, Z., Faussat, A.-M., Sayada, L., Perrot, J.-Y., Chaoui, D., Marie, J.-P. & Legrand, O. (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clinical Cancer Research, 10, 7896-7902.
4. Bonnet, D. & Dick, J.E. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730-737.
5. Borowitz, M.J., Gockerman, J.P., Moore, J.O., Civin, C.I., Page, S.O., Robertson, J. & Bigner, S.H. (1989) Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. American Journal of Clinical Pathology, 91, 265-270.
6. Bradstock, K., Matthews, J., Benson, E., Page, F. & Bishop, J. (1994) Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood, 84, 1220-1225.
7. Campos, L., Guyotat, D., Archimbaud, E., Devaux, Y., Treille, D., Larese, A., Maupas, J., Gentilhomme, O., Ehrsam, A. & Fiere, D. (1989) Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. British Journal of Haematology, 72, 161-166.
8. Ciolli, S., Leoni, F., Caporale, R., Pascarella, A., Salti, F. & Rossi-Ferrini, P. (1993) CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica, 78, 151-155.
9. Costello, R.T., Mallet, F., Gaugler, B., Sainty, D., Arnoulet, C., Gastaut, J.A & Olive, D. (2000) Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Research, 60, 4403-4411.
10. Dang, H., Chen, Y., Kamel-Reid, S., Brandwein, J. & Chang, H. (2013) CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Human pathology, 44, 2038-2046.
11. Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, M.C., Bruno, A., Buccisano, F., Masi, M., Tribalto, M., Amadori, S. & Papa, G. (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood, 87, 1997-2004.
12. Díez-Campelo, M., Pérez-Simón, J.A., Pérez, J., Alcoceba, M., Richtmon, J., Vidriales, B. & San Miguel, J. (2009) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. American Journal of Hematology, 84, 149-152.
13. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.-G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. The New England journal of Medicine, 352, 254-266.
14. Feller, N., van der Pol, M.A., van Stijn, A., Weijers, G.W.D., Westra, A.H., Evertse, B.W., Ossenkoppele, G.J. & Schuurhuis, G.J. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia, 18, 1380-1390.
15. Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association, 94, 496-509.
16. Freeman, S.D., Virgo, P., Couzens, S., Grimwade, D., Russell, N., Hills, R.K. & Burnett, A.K. (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. Journal of Clinical Oncology, 31, 4123-4131.
17. Fruchart, C., Lenormand, B., Bastard, C., Boulet, D., Lesesve, J.F., Callat, M.P., Stamatoullas, A., Monconduit, M. & Tilly, H. (1996) Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. American Journal of Hematology, 53, 175-180.
18. Goardon, N., Marchi, E., Atzberger, A., Quek, L., Schuh, A., Soneji, S., Woll, P., Mead, A., Alford, K.A., Rout, R., Chaudhury, S., Gilkes, A., Knapper, S., Beldjord, K., Begum, S., Rose, S., Geddes, N., Griffiths, M., Standen, G., Sternberg, A., Cavenagh, J., Hunter, H., Bowen, D., Killick, S., Robinson, L., Price, A., Macintyre, E., Virgo, P., Burnett, A., Craddock, C., Enver, T., Jacobsen, S.E.W. & Porcher, C. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell, 19, 138-152.
19. Guzman, M.L. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301-2307.
20. Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., Tomiyama, H., Saito, N., Fukata, M., Miyamoto, T., Lyons, B., Ohshima, K., Uchida, N., Taniguchi, S., Ohara, O., Akashi, K., Harada, M. & Shultz, L.D. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature Biotechnology, 25, 1315-1321.
21. Kanda, Y., Hamaki, T., Yamamoto, R., Chizuka, A., Suguro, M., Matsuyama, T., Takezako, N., Miwa, A., Kami, M., Hirai, H. & Togawa, A. (2000) The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer, 88, 2529-2533.
22. Kern, W., Voskova, D., Schoch, C., Hiddemann, W., Schnittger, S. & Haferlach, T. (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood, 104, 3078-3085.
23. Kyoda, K., Nakamura, S., Hattori, N., Takeshima, M., Nakamura, K., Kaya, H., Matano, S., Okumura, H., Kanno, M., Ohtake, S. & Matsuda, T. (1998) Lack of prognostic significance of CD34 expression in adult AML when FAB M0 and M3 are excluded. American Journal of Hematology, 57, 265-266.
24. Lamy, T., Goasguen, J.E., Mordelet, E., Grulois, I., Dauriac, C., Drenou, B., Chaperon, J., Fauchet, R. & le Prise, P.Y. (1994) P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia, 8, 1879-1883.
25. Lee, E.J., Yang, J., Leavitt, R.D., Testa, J.R., Civin, C.I., Forrest, A. & Schiffer, C.A. (1992) The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia, 6, 1203-1209.
26. Martelli, M.P., Pettirossi, V., Thiede, C., Bonifacio, E., Mezzasoma, F., Cecchini, D., Pacini, R., Tabarrini, A., Ciurnelli, R., Gionfriddo, I., Manes, N., Rossi, R., Giunchi, L., Oelschlägel, U., Brunetti, L., Gemei, M., Delia, M., Specchia, G., Liso, A., Di Ianni, M., Di Raimondo, F., Falzetti, F., Del Vecchio, L., Martelli, M.F. & Falini, B. (2010) CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood, 116, 3907-3922.
27. Maurillo, L., Buccisano, F., Del Principe, M.I., Del Poeta, G., Spagnoli, A., Panetta, P., Ammatuna, E., Neri, B., Ottaviani, L., Sarlo, C., Venditti, D., Quaresima, M., Cerretti, R., Rizzo, M., de Fabritiis, P., Lo Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2008) Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. Journal of Clinical Oncology, 26, 4944-4951.
28. Myint, H. & Lucie, N.P. (1992) The prognostic significance of the CD34 antigen in acute myeloid leukaemia. Leukemia & Lymphoma, 7, 425-429.
29. Ossenkoppele, G.J., van de Loosdrecht, A.A. & Schuurhuis, G.J. (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. British Journal of Haematology, 153, 421-436.
30. Pabst, T., Vellenga, E., van Putten, W., Schouten, H.C., Graux, C., Vekemans, M.-C., Biemond, B., Sonneveld, P., Passweg, J., Verdonck, L., Legdeur, M.-C., Theobald, M., Jacky, E., Bargetzi, M., Maertens, J., Ossenkoppele, G.J. & Löwenberg, B. (2012) Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood, 119, 5367-5373.
31. van der Pol, M.A., Feller, N., Roseboom, M., Moshaver, B., Westra, G., Broxterman, H.J., Ossenkoppele, G.J. & Schuurhuis, G.J. (2003a) Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica, 88, 983-993.
32. van der Pol, M.A., Feller, N., Ossenkoppele, G.J., Weijers, G.W.D., Westra, A.H., van Stijn, A., Broxterman, H.J. & Schuurhuis, G.J. (2003b) Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis. Leukemia, 17, 1674-1677.
33. Ran, D., Schubert, M., Pietsch, L., Taubert, I., Wuchter, P., Eckstein, V., Bruckner, T., Zoeller, M. & Ho, A.D. (2009) Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Experimental Hematology, 37, 1423-1434.
34. Raspadori, D., Lauria, F., Ventura, M.A., Rondelli, D., Visani, G., de Vivo, A. & Tura, S. (1997) Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leukemia Research, 21, 603-607.
35. Rockova, V., Abbas, S., Wouters, B.J., Erpelinck, C.A.J., Beverloo, H.B., Delwel, R., van Putten, W.L.J., Löwenberg, B. & Valk, P.J.M. (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood, 118, 1069-1076.
36. San Miguel, J.F., Vidriales, M.B., López-Berges, C., Díaz-Mediavilla, J., Gutiérrez, N., Cañizo, C., Ramos, F., Calmuntia, M.J., Pérez, J.J., González, M. & Orfao, A. (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 98, 1746-1751.
37. Sarry, J.-E., Murphy, K., Perry, R., Sanchez, P.V., Secreto, A., Keefer, C., Swider, C.R., Strzelecki, A.-C., Cavelier, C., Récher, C., Mansat-De Mas, V., Delabesse, E., Danet-Desnoyers, G. & Carroll, M. (2011) Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. The Journal of Clinical Investigation, 121, 384-395.
38. Schuurhuis, G.J., Meel, M.H., Wouters, F., Min, L.A., Terwijn, M., de Jonge, N.A., Kelder, A., Snel, A.N., Zweegman, S., Ossenkoppele, G.J. & Smit, L. (2013) Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS ONE, 8, e78897.
39. Selleri, C., Notaro, R., Catalano, L., Fontana, R., Del Vecchio, L. & Rotoli, B. (1992) Prognostic irrelevance of CD34 in acute myeloid leukaemia. British Journal of Haematology, 82, 479-481.
40. Solary, E., Casasnovas, R.O., Campos, L., Béné, M.C., Faure, G., Maingon, P., Falkenrodt, A., Lenormand, B. & Genetet, N. (1992) Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL). Leukemia, 6, 393-399.
41. Suárez, L., Vidriales, M.-B., García-Laraña, J., Sanz, G., Moreno, M.-J., López, A., Barrena, S., Martínez, R., Tormo, M., Palomera, L., Lavilla, E., López-Berges, M.C., de Santiago, M., de Equiza, M.E.P., Miguel, J.F.S. & Orfao, A. (2004) CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clinical Cancer Research, 10, 7599-7606.
42. Taussig, D.C., Vargaftig, J., Miraki-Moud, F., Griessinger, E., Sharrock, K., Luke, T., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S.G., Lister, T.A., Gribben, J.G. & Bonnet, D. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood, 115, 1976-1984.
43. Te Boekhorst, P.A., de Leeuw, K., Schoester, M., Wittebol, S., Nooter, K., Hagemeijer, A., Löwenberg, B. & Sonneveld, P. (1993) Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood, 82, 3157-3162.
44. Terwijn, M., van Putten, W.L.J., Kelder, A., van der Velden, V.H.J., Brooimans, R.A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G.E., Valk, P.J.M., Preijers, F.W.M.B., Huijgens, P.C., Dräger, A.M., Schanz, U., Jongen-Lavrecic, M., Biemond, B.J., Passweg, J.R., van Gelder, M., Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.-C., Kuball, J., de Weerdt, O., Chalandon, Y., Hess, U., Verdonck, L.F., Gratama, J.W., Oussoren, Y.J.M., Scholten, W.J., Slomp, J., Snel, A.N., Vekemans, M.-C., Löwenberg, B., Ossenkoppele, G.J. & Schuurhuis, G.J. (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of Clinical Oncology, 31, 3889-3897.
45. Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A.P., Snel, A.N., Scholten, W.J., Pabst, T., Verhoef, G., Löwenberg, B., Zweegman, S., Ossenkoppele, G.J. & Schuurhuis, G.J. (2014) Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE, 9, e107587.
46. Van den Heuvel-Eibrink, M.M., van der Holt, B., te Boekhorst, P.A., Pieters, R., Schoester, M., Löwenberg, B. & Sonneveld, P. (1997) MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. British Journal of Haematology, 99, 76-83.
47. Van den Heuvel-Eibrink, M.M., van der Holt, B., Burnett, A.K., Knauf, W.U., Fey, M.F., Verhoef, G.E.G., Vellenga, E., Ossenkoppele, G.J., Löwenberg, B. & Sonneveld, P. (2007) CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of Hematology, 86, 329-337.
48. Van Stijn, A., van der Pol, M.A., Kok, A., Bontje, P.M., Roemen, G.M.J.M., Beelen, R.H.J., Ossenkoppele, G.J. & Schuurhuis, G.J. (2003) Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica, 88, 497-508.
49. Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M. & Amadori, S. (2000) Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, 96, 3948-3952.
50. Vergez, F., Green, A.S., Tamburini, J., Sarry, J.-E., Gaillard, B., Cornillet-Lefebvre, P., Pannetier, M., Neyret, A., Chapuis, N., Ifrah, N., Dreyfus, F., Manenti, S., Demur, C., Delabesse, E., Lacombe, C., Mayeux, P., Bouscary, D., Recher, C. & Bardet, V. (2011) High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 96, 1792-1798.
51. Zhou, D.C., Zittoun, R. & Marie, J.P. (1995) Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia, 9, 1661-1666.
52. Zhu, H.-H., Liu, Y.-R., Jiang, H., Lu, J., Qin, Y.-Z., Jiang, Q., Bao, L., Ruan, G.-R., Jiang, B. & Huang, X. (2013) CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation. Leukemia Research, 37, 624-630.